Facebook Linkedin RSS Twitter Youtube
Home 2024

AbbVie

Seaport Eyes Platform, Pipeline Growth with $225M Series B
Drug Discovery

Seaport Eyes Platform, Pipeline Growth with $225M Series B

StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints
Drug Discovery

StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints

Top 10 Best Selling Drugs
A-Lists

Top 10 Best Selling Drugs

StockWatch: Insmed Shares Leap 150%, as Analysts See Next Blockbuster
Drug Discovery

StockWatch: Insmed Shares Leap 150%, as Analysts See Next Blockbuster

Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders
Drug Discovery

Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III
Drug Discovery

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III

Bioconjugates Meet and Promise to Exceed Expectations
Drug Discovery

Bioconjugates Meet and Promise to Exceed Expectations

Smart Biomanufacturing: From Piecemeal to All of a Piece
Bioprocessing

Smart Biomanufacturing: From Piecemeal to All of a Piece

AbbVie to Acquire Cerevel for $8.7B, Growing Neuro Drug Pipeline
Drug Discovery

AbbVie to Acquire Cerevel for $8.7B, Growing Neuro Drug Pipeline

AbbVie to Acquire ImmunoGen for $10.1B, Expanding Cancer Franchise
Cancer

AbbVie to Acquire ImmunoGen for $10.1B, Expanding Cancer Franchise

123...9Page 1 of 9
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.